Fresh analysis reveals that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a prominent health publication shows that while overweight people can lose a large proportion of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using such treatments need to be informed of the potential of fast weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a reversion to starting mass within about one and a half years.
Weighing Approaches
The study, which reviewed 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
Scientists emphasize that individuals who shed pounds through diet and exercise generally see a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Fast Rebound
Doctors propose the mode of action of the drugs explains the amplified rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal may cause the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is unsuppressed, making overeating much more probable."
A Lifelong Condition?
The NHS advise the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, due to the significant potential of weight regain, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who state that the results "highlight the persistent nature of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs explain a intense resurgence of cravings.
"I experienced a trigger flipping and you become extremely hungry," said a patient.
The struggle is compounded if patients have not adopted lasting lifestyle or habit changes during therapy.
Widespread Use
Recent estimates show that a significant number of people in the UK have used these injections in the past year, with desire being substantial.
- Adoption is greater among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while the jabs are potent agents for weight loss, they are not a standalone cure and long-term success likely depends on combined lifestyle management.
